Ming-Chih Jeffrey Kao, MD
Pain Management · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 4
Offices
4 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kao’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A105859 · Current
Licensed to practise in California · since 2008 · expires 2028-09-30 · University of Michigan Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$104,121
Medicare paid this office $104,121 for 308 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Botox | 14 | $26,349 | None |
| Return visit (30+ min) | 140 | $24,027 | $116 |
| New patient visit (60+ min) | 55 | $10,396 | $189 |
| New patient visit (45+ min) | 55 | $8,745 | $159 |
| Injection of trigger points, 3 or more muscles | 49 | $4,993 | $51 |
See all 14 services
| Botox | 14 | $26,349 | None |
| Return visit (30+ min) | 140 | $24,027 | $116 |
| New patient visit (60+ min) | 55 | $10,396 | $189 |
| New patient visit (45+ min) | 55 | $8,745 | $159 |
| Injection of trigger points, 3 or more muscles | 49 | $4,993 | $51 |
| Ultrasonic guidance for needle placement | 80 | $4,327 | $28 |
| Long return visit (40+ min) | 25 | $3,641 | $140 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 12 | $2,571 | $122 |
| Injection of trigger points, 1-2 muscles | 41 | $2,438 | $45 |
| Short return visit (20+ min) | 28 | $2,412 | $78 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 16 | $2,175 | $104 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 96 | $1,887 | $15 |
| Injection, ropivacaine hydrochloride, 1 mg | 77 | $564 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 32 | $124 | None |
Who their Medicare patients are
308 Original Medicare patients in 2024. Average age 72 · Under 65 20% · 85 and older 11% · Women 70% · Also on Medicaid 28% · Health risk score 1.55. Above the middle of the specialty; the typical pain management clinician is at 1.38.
Conditions among them: High blood pressure 70% · Depression 36% · Diabetes 32% · Chronic kidney disease 25% · Coronary heart disease 24% · Cancer 22% · Atrial fibrillation 18% · Heart failure 17% · COPD 14% · Stroke 10% · Dementia 6%.
The office billed $725,673, Medicare allowed $134,522 and paid $104,121; for 18,627 services of 39 kinds; $31,415 of it was for drugs given in the office and $72,706 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 308 | 18,627 | 72 | 1.55 | $725,673 | $104,121 |
| 2023 | 296 | 7,350 | 69 | 1.63 | $720,716 | $73,833 |
| 2022 | 215 | 378 | 68 | 1.50 | $159,073 | $24,153 |
| 2021 | 305 | 644 | 67 | 1.49 | $538,142 | $47,486 |
| 2020 | 333 | 817 | 67 | 1.67 | $590,790 | $56,709 |
| 2019 | 413 | 1,171 | 68 | 1.62 | $528,170 | $80,892 |
| 2018 | 411 | 1,281 | 67 | 1.57 | $629,921 | $85,921 |
| 2017 | 350 | 910 | 68 | 1.44 | $624,023 | $68,288 |
| 2016 | 355 | 814 | 66 | 1.42 | $433,247 | $59,009 |
| 2015 | 360 | 843 | 65 | 1.71 | $469,815 | $60,149 |
| 2014 | 363 | 735 | 66 | 1.53 | $275,728 | $54,149 |
| 2013 | 88 | 129 | 65 | 1.80 | $65,919 | $9,899 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| New patient visit (60+ min) | 81 | $16,233 | $200 |
| Return visit (30+ min) | 95 | $13,510 | $109 |
| Botox | 12 | $10,691 | None |
| Long return visit (40+ min) | 44 | $7,574 | $155 |
| Injection of trigger points, 3 or more muscles | 57 | $3,948 | $44 |
| New patient visit (45+ min) | 25 | $3,745 | $150 |
| Ultrasonic guidance for needle placement | 70 | $3,040 | $27 |
| Telehealth originating site facility fee | 81 | $2,248 | $22 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 13 | $2,069 | $115 |
| Injection of trigger points, 1-2 muscles | 36 | $1,881 | $43 |
| Short return visit (20+ min) | 19 | $1,315 | $69 |
| Chronic pain management and treatment, monthly bundle including, diagnosis; assessment and monitoring; administration of a validated pain rating scale or tool; the development, implementation, revision, and/or maintenance of a person-centered care plan tha | 14 | $1,149 | $77 |
| Administration of psychological or neuropsychological test, first 30 minutes | 15 | $646 | $43 |
| Injection, ropivacaine hydrochloride, 1 mg | 58 | $253 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 16 | $50 | None |
2022: 8 services
| Return visit (30+ min) | 56 | $5,945 | $83 |
| New patient visit (60+ min) | 21 | $3,452 | $164 |
| Injection of trigger points, 3 or more muscles | 37 | $2,334 | $38 |
| Long return visit (40+ min) | 18 | $2,021 | $112 |
| Short return visit (20+ min) | 34 | $1,929 | $52 |
| New patient visit (45+ min) | 17 | $1,900 | $112 |
| Injection of trigger points, 1-2 muscles | 33 | $1,628 | $32 |
| Aspiration and/or injection of fluid from large joint | 13 | $687 | $38 |
2021: 11 services
| Return visit (30+ min) | 109 | $12,465 | $87 |
| New patient visit (60+ min) | 36 | $6,186 | $172 |
| Long return visit (40+ min) | 29 | $4,342 | $132 |
| Short return visit (20+ min) | 50 | $3,151 | $61 |
| New patient visit (45+ min) | 23 | $2,873 | $125 |
| Ultrasonic guidance for needle placement | 63 | $2,268 | $27 |
| Injection of trigger points, 3 or more muscles | 24 | $1,081 | $36 |
| Telephone medical discussion with physician, 11-20 minutes | 15 | $820 | $51 |
| Injection of trigger points, 1-2 muscles | 20 | $643 | $32 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 15 | $613 | $32 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 25 | $294 | $10 |
2020: 13 services
| Return visit (30+ min) | 120 | $11,840 | $74 |
| New patient visit (60+ min) | 73 | $11,075 | $152 |
| Long return visit (40+ min) | 61 | $7,107 | $102 |
| New patient visit (45+ min) | 18 | $2,211 | $123 |
| Ultrasonic guidance for needle placement | 57 | $2,104 | $28 |
| Telephone medical discussion with physician, 21-30 minutes | 20 | $1,771 | $77 |
| Short return visit (20+ min) | 34 | $1,604 | $47 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 14 | $1,056 | $56 |
| Telephone medical discussion with physician, 11-20 minutes | 20 | $1,022 | $51 |
| Injection of trigger points, 3 or more muscles | 19 | $955 | $40 |
| Telehealth originating site facility fee | 25 | $527 | $21 |
| Injection of trigger points, 1-2 muscles | 14 | $485 | $27 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 31 | $403 | $11 |
2019: 14 services
| Long return visit (40+ min) | 158 | $21,805 | $101 |
| New patient visit (60+ min) | 96 | $14,443 | $150 |
| Return visit (30+ min) | 117 | $10,473 | $71 |
| Ultrasonic guidance for needle placement | 109 | $5,319 | $29 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 21 | $4,814 | $105 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 33 | $2,698 | $59 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 34 | $2,248 | $41 |
| Injection of trigger points, 3 or more muscles | 30 | $2,134 | $34 |
| Injection of trigger points, 1-2 muscles | 51 | $1,647 | $27 |
| Injection of chemical for paralysis of nerve muscles on side of voice box | 16 | $1,487 | $83 |
| Short return visit (20+ min) | 16 | $763 | $48 |
| Other procedure on nervous system | 13 | $517 | $26 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 15 | $176 | $11 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 11 | $125 | $10 |
2018: 17 services
| Long return visit (40+ min) | 153 | $22,966 | $95 |
| New patient visit (60+ min) | 104 | $14,999 | $144 |
| Return visit (30+ min) | 80 | $5,936 | $66 |
| Ultrasonic guidance for needle placement | 127 | $5,445 | $28 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 33 | $4,606 | $100 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 15 | $3,637 | $214 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 38 | $3,152 | $59 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 46 | $3,012 | $40 |
| Injection of trigger points, 3 or more muscles | 51 | $2,749 | $34 |
| Injection of trigger points, 1-2 muscles | 46 | $1,413 | $25 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 17 | $1,381 | $81 |
| Injection of substance into lower spine canal using imaging guidance | 13 | $1,304 | $87 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 12 | $830 | $55 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 61 | $776 | $11 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 14 | $676 | $48 |
| Other procedure on nervous system | 12 | $459 | $35 |
| Injection into tendon or ligament | 11 | $321 | $23 |
2017: 15 services
| Long return visit (40+ min) | 109 | $13,122 | $95 |
| New patient visit (60+ min) | 89 | $12,857 | $144 |
| Return visit (30+ min) | 79 | $6,698 | $66 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 18 | $5,386 | $234 |
| New patient visit (45+ min) | 26 | $2,783 | $107 |
| Ultrasonic guidance for needle placement | 72 | $2,605 | $28 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 28 | $1,681 | $43 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 15 | $1,617 | $108 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 15 | $1,571 | $58 |
| Injection of substance into lower spine canal using imaging guidance | 14 | $1,267 | $84 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 81 | $1,090 | $11 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 14 | $1,003 | $48 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 13 | $740 | $57 |
| Injection of trigger points, 1-2 muscles | 20 | $668 | $32 |
| Injection of trigger points, 3 or more muscles | 18 | $652 | $34 |
2016: 11 services
| Return visit (30+ min) | 121 | $12,654 | $65 |
| New patient visit (60+ min) | 84 | $11,909 | $142 |
| Long return visit (40+ min) | 58 | $6,001 | $94 |
| New patient visit (45+ min) | 35 | $4,077 | $116 |
| Ultrasonic guidance for needle placement | 73 | $2,701 | $30 |
| Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes | 61 | $2,495 | $38 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 32 | $1,758 | $45 |
| Destruction of peripheral nerve or branch | 14 | $1,304 | $93 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 13 | $904 | $50 |
| Injection of trigger points, 3 or more muscles | 19 | $887 | $35 |
| Injection of trigger points, 1-2 muscles | 19 | $693 | $28 |
2015: 14 services
| Return visit (30+ min) | 144 | $14,538 | $67 |
| New patient visit (60+ min) | 88 | $12,433 | $141 |
| Long return visit (40+ min) | 42 | $4,470 | $95 |
| New patient visit (45+ min) | 25 | $2,775 | $111 |
| Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes | 65 | $2,620 | $37 |
| Ultrasonic guidance for needle placement | 63 | $2,599 | $29 |
| Short return visit (20+ min) | 42 | $2,045 | $44 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 13 | $1,578 | $121 |
| Injections of substances into lower or sacral spine | 18 | $1,465 | $77 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 11 | $1,150 | $105 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 20 | $934 | $39 |
| Injection of trigger points, 3 or more muscles | 17 | $827 | $36 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 11 | $638 | $58 |
| Injection of trigger points, 1-2 muscles | 18 | $502 | $25 |
2014: 12 services
| New patient visit (60+ min) | 99 | $14,575 | $147 |
| Return visit (30+ min) | 145 | $13,597 | $66 |
| Long return visit (40+ min) | 51 | $5,189 | $98 |
| New patient visit (45+ min) | 41 | $4,630 | $113 |
| Short return visit (20+ min) | 55 | $2,811 | $43 |
| Ultrasonic guidance for needle placement | 56 | $1,965 | $30 |
| Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes | 34 | $1,343 | $38 |
| Injections of substances into lower or sacral spine | 13 | $858 | $66 |
| Injection of trigger points, 3 or more muscles | 18 | $766 | $38 |
| Injection of trigger points, 1-2 muscles | 23 | $760 | $28 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 14 | $724 | $45 |
| Fluoroscopic guidance for spine or back muscle injection | 13 | $355 | $27 |
2013: 3 services
| Return visit (30+ min) | 38 | $3,036 | $66 |
| New patient visit (60+ min) | 13 | $1,884 | $145 |
| Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes | 12 | $458 | $38 |
Medicaid work
$9,717 in 2024
Medicaid paid $9,717 for 173 billed services this clinician did in 2024, up to 24 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 159 | $9,657 |
| Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation | 14 | $60 |
| 2024 | 173 | 2 | 24 | $9,717 |
| 2023 | 13 | 1 | 13 | $304 |
| 2021 | 83 | 2 | 16 | $3,130 |
| 2020 | 104 | 1 | 18 | $2,973 |
| 2019 | 185 | 2 | 20 | $5,150 |
| 2018 | 13 | 1 | 13 | $340 |
See the largest Medicaid services in earlier years
2023
| Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation | 13 | $304 |
2021
| Return visit (30+ min) | 69 | $2,928 |
| Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation | 14 | $201 |
2020
| Return visit (30+ min) | 104 | $2,973 |
2019
| Return visit (30+ min) | 151 | $4,235 |
| Short return visit (20+ min) | 34 | $915 |
2018
| Return visit (30+ min) | 13 | $340 |
Drugs they prescribed that Part D paid
$46,894
Pharmacies billed $46,894 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 12% of their Part D prescriptions (80 of 661) in 2024. At or below the middle of the specialty; the typical pain management clinician is at 44%. Long-acting opioids: 63% of their opioid prescriptions.
620 generic and 41 brand-name prescriptions · $46,894 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Emgality | Migraine | 14 | $10,064 | $719 |
| Buprenorphine | None | 32 | $5,791 | $181 |
| Pregabalin | None | 103 | $3,216 | $31 |
| Gabapentin | None | 96 | $2,818 | $29 |
| Duloxetine | None | 121 | $2,013 | $17 |
See all 14 drugs
| Emgality | Migraine | 14 | $10,064 | $719 |
| Buprenorphine | None | 32 | $5,791 | $181 |
| Pregabalin | None | 103 | $3,216 | $31 |
| Gabapentin | None | 96 | $2,818 | $29 |
| Duloxetine | None | 121 | $2,013 | $17 |
| Baclofen | None | 73 | $1,858 | $25 |
| Tizanidine | None | 22 | $1,256 | $57 |
| Celecoxib | None | 21 | $993 | $47 |
| Diclofenac | None | 12 | $214 | $18 |
| Methadone | None | 11 | $208 | $19 |
| Oxycodone | None | 11 | $182 | $17 |
| Sumatriptan | None | 14 | $109 | $8 |
| Topiramate | None | 24 | $104 | $4 |
| Meloxicam | None | 30 | $77 | $3 |
Year by year
| 2024 | 661 | 136 | 12% (80) | 6% | $46,894 |
| 2023 | 307 | 80 | 15% (46) | 4% | $29,531 |
| 2022 | 365 | 76 | 12% (45) | 16% | $73,861 |
| 2021 | 656 | 114 | 15% (101) | 11% | $69,199 |
| 2020 | 1,204 | 181 | 16% (193) | 11% | $126,107 |
| 2019 | 1,286 | 205 | 17% (223) | 22% | $200,476 |
| 2018 | 1,006 | 189 | 10% (102) | 24% | $157,772 |
| 2017 | 1,029 | 221 | 9% (90) | 23% | $132,206 |
| 2016 | 1,030 | 238 | 7% (69) | 23% | $125,273 |
| 2015 | 965 | 222 | 7% (65) | 20% | $102,395 |
| 2014 | 562 | 174 | 16% (90) | 30% | $62,018 |
| 2013 | 78 | 36 | 15% (12) | 29% | $8,845 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Pregabalin | 64 | $3,091 | $48 |
| Gabapentin | 39 | $2,389 | $61 |
| Celecoxib | 21 | $1,272 | $61 |
| Tizanidine | 14 | $1,215 | $87 |
| Baclofen | 38 | $967 | $25 |
| Duloxetine | 26 | $776 | $30 |
| Topiramate | 21 | $367 | $17 |
| Oxycodone | 13 | $116 | $9 |
2022: 11 drugs
| Emgality | Migraine | 32 | $30,769 | $962 |
| Buprenorphine | None | 14 | $7,461 | $533 |
| Pregabalin | None | 71 | $3,570 | $50 |
| Gabapentin | None | 21 | $1,092 | $52 |
| Celecoxib | None | 16 | $1,033 | $65 |
| Duloxetine | None | 23 | $764 | $33 |
| Levetiracetam | None | 21 | $638 | $30 |
| Oxcarbazepine | None | 20 | $593 | $30 |
| Baclofen | None | 17 | $527 | $31 |
| Topiramate | None | 20 | $355 | $18 |
| Sumatriptan | None | 16 | $292 | $18 |
2021: 17 drugs
| Emgality | Migraine | 30 | $22,449 | $748 |
| Pregabalin | None | 151 | $12,569 | $83 |
| Buprenorphine | None | 22 | $8,443 | $384 |
| Baclofen | None | 36 | $1,843 | $51 |
| Duloxetine | None | 73 | $1,843 | $25 |
| Gabapentin | None | 41 | $1,467 | $36 |
| Celecoxib | None | 17 | $679 | $40 |
| Buprenorphine | None | 12 | $544 | $45 |
| Levetiracetam | None | 22 | $431 | $20 |
| Diclofenac | None | 16 | $369 | $23 |
| Topiramate | None | 30 | $320 | $11 |
| Oxycodone | None | 30 | $287 | $10 |
| Tizanidine | None | 17 | $249 | $15 |
| Hydrocodone-Acetaminophen | None | 19 | $215 | $11 |
| Sumatriptan | None | 16 | $205 | $13 |
| Venlafaxine Hcl Er | None | 13 | $130 | $10 |
| Ibuprofen | None | 11 | $60 | $5 |
2020: 28 drugs
| Emgality | Migraine | 39 | $25,649 | $658 |
| Buprenorphine | None | 55 | $25,352 | $461 |
| Pregabalin | None | 230 | $13,477 | $59 |
| Butrans | None | 14 | $9,606 | $686 |
| Lyrica | None | 11 | $8,426 | $766 |
| Emgality | Migraine | 11 | $7,260 | $660 |
| Gabapentin | None | 87 | $4,172 | $48 |
| Duloxetine | None | 139 | $3,993 | $29 |
| Baclofen | None | 79 | $3,758 | $48 |
| Diclofenac | None | 64 | $2,322 | $36 |
| Dantrolene | None | 12 | $1,284 | $107 |
| Fentanyl | None | 16 | $1,268 | $79 |
| Buprenorphine | None | 18 | $905 | $50 |
| Topiramate | None | 72 | $851 | $12 |
| Tizanidine | None | 18 | $792 | $44 |
| Oxcarbazepine | None | 14 | $702 | $50 |
| Oxycodone-Acetaminophen | None | 16 | $701 | $44 |
| Methocarbamol | None | 16 | $664 | $41 |
| Morphine Sulfate Er | None | 11 | $525 | $48 |
| Celecoxib | None | 14 | $517 | $37 |
| Hydrocodone-Acetaminophen | None | 23 | $505 | $22 |
| Levetiracetam | None | 22 | $480 | $22 |
| Cyclobenzaprine | None | 13 | $416 | $32 |
| Oxycodone | None | 30 | $385 | $13 |
| Methadone | None | 16 | $353 | $22 |
| Sumatriptan | None | 28 | $328 | $12 |
| Naproxen | None | 16 | $305 | $19 |
| Meloxicam | None | 15 | $135 | $9 |
2019: 31 drugs
| Lyrica | None | 103 | $69,465 | $674 |
| Emgality | Migraine | 27 | $19,707 | $730 |
| Buprenorphine | None | 44 | $18,753 | $426 |
| Aimovig | Migraine | 13 | $12,463 | $959 |
| Oxycontin | None | 24 | $10,139 | $422 |
| Pregabalin | None | 81 | $8,164 | $101 |
| Duloxetine | None | 143 | $6,931 | $48 |
| Gabapentin | None | 108 | $4,215 | $39 |
| Buprenorphine | None | 28 | $2,781 | $99 |
| Baclofen | None | 77 | $1,976 | $26 |
| Narcan | None | 15 | $1,927 | $128 |
| Celecoxib | None | 25 | $1,754 | $70 |
| Oxycodone | None | 43 | $970 | $23 |
| Clonidine | None | 11 | $939 | $85 |
| Voltaren | None | 15 | $824 | $55 |
| Diclofenac | None | 25 | $780 | $31 |
| Topiramate | None | 75 | $758 | $10 |
| Levetiracetam | None | 38 | $703 | $19 |
| Hydrocodone-Acetaminophen | None | 33 | $672 | $20 |
| Oxcarbazepine | None | 20 | $550 | $27 |
| Fentanyl | None | 12 | $510 | $43 |
| Tizanidine | None | 25 | $501 | $20 |
| Nortriptyline | None | 20 | $422 | $21 |
| Methadone | None | 19 | $413 | $22 |
| Cyclobenzaprine | None | 18 | $403 | $22 |
| Morphine Sulfate Er | None | 13 | $339 | $26 |
| Oxycodone-Acetaminophen | None | 13 | $330 | $25 |
| Sumatriptan | None | 33 | $278 | $8 |
| Venlafaxine Hcl Er | None | 11 | $170 | $15 |
| Naproxen | None | 12 | $157 | $13 |
| Meloxicam | None | 17 | $54 | $3 |
2018: 20 drugs
| Lyrica | 136 | $89,398 | $657 |
| Buprenorphine | 29 | $11,967 | $413 |
| Butrans | 11 | $7,328 | $666 |
| Suboxone | 16 | $7,109 | $444 |
| Duloxetine | 114 | $4,492 | $39 |
| Gabapentin | 125 | $2,879 | $23 |
| Baclofen | 89 | $1,859 | $21 |
| Dantrolene | 19 | $1,760 | $93 |
| Diclofenac | 26 | $1,043 | $40 |
| Oxcarbazepine | 22 | $879 | $40 |
| Topiramate | 90 | $685 | $8 |
| Nortriptyline | 26 | $620 | $24 |
| Voltaren | 11 | $605 | $55 |
| Tizanidine | 24 | $603 | $25 |
| Levetiracetam | 49 | $592 | $12 |
| Oxycodone | 20 | $505 | $25 |
| Methadone | 14 | $325 | $23 |
| Naproxen | 13 | $154 | $12 |
| Sumatriptan | 20 | $86 | $4 |
| Meloxicam | 14 | $55 | $4 |
2017: 22 drugs
| Lyrica | 127 | $66,258 | $522 |
| Butrans | 28 | $14,789 | $528 |
| Cromolyn | 14 | $6,608 | $472 |
| Suboxone | 19 | $6,517 | $343 |
| Movantik | 16 | $5,087 | $318 |
| Duloxetine | 78 | $4,430 | $57 |
| Gabapentin | 101 | $3,701 | $37 |
| Oxcarbazepine | 77 | $2,453 | $32 |
| Dantrolene | 31 | $2,197 | $71 |
| Lidocaine | 12 | $2,078 | $173 |
| Baclofen | 88 | $1,434 | $16 |
| Nortriptyline | 39 | $1,423 | $36 |
| Clonidine | 16 | $1,145 | $72 |
| Topiramate | 128 | $1,115 | $9 |
| Levetiracetam | 53 | $882 | $17 |
| Tizanidine | 24 | $691 | $29 |
| Voltaren | 11 | $627 | $57 |
| Sumatriptan | 11 | $375 | $34 |
| Hydrocodone-Acetaminophen | 19 | $193 | $10 |
| Amitriptyline | 12 | $181 | $15 |
| Naproxen | 12 | $105 | $9 |
| Cyclobenzaprine | 14 | $23 | $2 |
2016: 16 drugs
| Lyrica | 132 | $63,654 | $482 |
| Lidocaine | 37 | $10,918 | $295 |
| Butrans | 20 | $7,722 | $386 |
| Gabapentin | 194 | $5,837 | $30 |
| Horizant | 17 | $5,710 | $336 |
| Movantik | 18 | $5,049 | $280 |
| Duloxetine | 89 | $5,029 | $57 |
| Suboxone | 12 | $2,927 | $244 |
| Hydrocodone-Acetaminophen | 25 | $2,459 | $98 |
| Oxcarbazepine | 67 | $2,255 | $34 |
| Baclofen | 108 | $2,059 | $19 |
| Dantrolene | 17 | $1,106 | $65 |
| Topiramate | 102 | $1,076 | $11 |
| Nortriptyline | 32 | $822 | $26 |
| Tizanidine | 11 | $469 | $43 |
| Nabumetone | 13 | $342 | $26 |
2015: 17 drugs
| Lyrica | 82 | $37,707 | $460 |
| Duloxetine | 86 | $8,675 | $101 |
| Horizant | 23 | $6,128 | $266 |
| Lidocaine | 34 | $5,004 | $147 |
| Butrans | 16 | $4,155 | $260 |
| Gabapentin | 137 | $3,992 | $29 |
| Voltaren | 44 | $2,484 | $56 |
| Baclofen | 105 | $1,745 | $17 |
| Nortriptyline | 60 | $1,145 | $19 |
| Topiramate | 101 | $1,005 | $10 |
| Tizanidine | 24 | $665 | $28 |
| Sumatriptan | 15 | $655 | $44 |
| Nabumetone | 24 | $562 | $23 |
| Venlafaxine | 26 | $501 | $19 |
| Oxcarbazepine | 22 | $484 | $22 |
| Oxycodone | 13 | $349 | $27 |
| Meloxicam | 12 | $51 | $4 |
2014: 13 drugs
| Lyrica | 54 | $22,600 | $419 |
| Duloxetine | 21 | $7,500 | $357 |
| Gabapentin | 126 | $3,696 | $29 |
| Voltaren | 58 | $2,652 | $46 |
| Oxycontin | 11 | $2,440 | $222 |
| Morphine Sulfate Er | 15 | $1,239 | $83 |
| Topiramate | 57 | $860 | $15 |
| Oxcarbazepine | 14 | $760 | $54 |
| Baclofen | 32 | $563 | $18 |
| Hydrocodone-Acetaminophen | 16 | $511 | $32 |
| Nortriptyline | 19 | $500 | $26 |
| Oxycodone | 16 | $351 | $22 |
| Tizanidine | 12 | $156 | $13 |
2013: 2 drugs
| Gabapentin | 27 | $1,285 | $48 |
| Baclofen | 12 | $176 | $15 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1922282870
- Licence
- CA A105859California A105859: Current · expires 2028-09-30
- Trained
- University of Michigan Medical School, 2007
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2081P2900X (2081P2900X); Federal specialty code 208100000X (208100000X)
- Mailing address
- 450 Broadway St, Stanford University Medical Center, Anesthesiology, Redwood City, CA, 94063
- NPI first listed
- 2007-12-27
- NPI last updated
- 2024-04-11
- NPI record certified
- 2024-04-11
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 450 Broadway St, Redwood City, CA, 94063